Alston & Bird Experts Assess Eli Lilly’s Belated DOJ Declination

Over two years after the SEC settled FCPA charges with pharmaceutical giant Eli Lilly, the company has announced that the DOJ has declined to bring charges relating to the same conduct.  Edward Kang, a partner at Alston & Bird, and senior associates Brian Frey and Jason Popp, discussed the compliance takeaways from the lagging declination and the enforcement climate for the pharmaceutical industry with The FCPA Report.  See “Pharma Giant Eli Lilly Agrees to $29.4 Million Consent Judgment to Settle SEC Charges of FCPA Violations Arising Out of Its Operations in Russia, China, Brazil and Poland,” The FCPA Report, Vol. 2, No. 1 (Jan. 9, 2013).

To read the full article

Continue reading your article with an ACR subscription.